SubHero Banner
Text

Tasigna® (nilotinib) – New and expanded indications, new warning

March 22, 2018 - The FDA approved Novartis’ Tasigna (nilotinib) for the treatment of pediatric patients ≥ 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP); and for the treatment of pediatric patients ≥ 1 year of age with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.

Download PDF